These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8245883)

  • 21. Valaciclovir: a review of its use in the management of herpes zoster.
    Ormrod D; Goa K
    Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy.
    Kimberlin DF; Weller S; Whitley RJ; Andrews WW; Hauth JC; Lakeman F; Miller G
    Am J Obstet Gynecol; 1998 Oct; 179(4):846-51. PubMed ID: 9790357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.
    Spruance SL; Tyring SK; DeGregorio B; Miller C; Beutner K
    Arch Intern Med; 1996 Aug 12-26; 156(15):1729-35. PubMed ID: 8694673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
    Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
    Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Valacyclovir].
    Biernat-Sudolska M
    Przegl Lek; 1998; 55(11):596-8. PubMed ID: 10216374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric uses of valacyclovir, penciclovir and famciclovir.
    Dekker CL; Prober CG
    Pediatr Infect Dis J; 2001 Nov; 20(11):1079-81. PubMed ID: 11734715
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers.
    Lin H; Tian Y; Tian JX; Zhang ZJ; Mao GG
    Arzneimittelforschung; 2010; 60(3):162-7. PubMed ID: 20422949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valacyclovir.
    Acosta EP; Fletcher CV
    Ann Pharmacother; 1997 Feb; 31(2):185-91. PubMed ID: 9034421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
    Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?].
    Peyrière H; Branger B; Bengler C; Vécina F; Pinzani V; Hillaire-Buys D; Blayac JP
    Rev Med Interne; 2001 Mar; 22(3):297-303. PubMed ID: 11270274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Valaciclovir].
    Taéron C
    Rev Infirm; 2007 Dec; (136):47-8. PubMed ID: 18257501
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
    Burnette TC; de Miranda P
    Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.
    Lycke J; Malmeström C; Ståhle L
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2438-41. PubMed ID: 12878501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.
    Reitano M; Tyring S; Lang W; Thoming C; Worm AM; Borelli S; Chambers LO; Robinson JM; Corey L
    J Infect Dis; 1998 Sep; 178(3):603-10. PubMed ID: 9728526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
    Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
    J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
    Bastiaans DE; Bartels-Wilmer CM; Colbers AP; Heijens CA; Velthoven-Graafland K; Smeets OS; Vink N; Harbers VE; Warris A; Burger DM
    Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
    [No Abstract]   [Full Text] [Related]  

  • 39. Rapid systemic valaciclovir reaction subsequent to aciclovir contact allergy.
    Lammintausta K; Mäkelä L; Kalimo K
    Contact Dermatitis; 2001 Sep; 45(3):181. PubMed ID: 11553156
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
    Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.